The authors also list iPSCs as resource from patients or carriers with the S305I (Kovacs et al., 2008), S305N (Hasegawa et al., 1999), and S305S (Stanford et al., 2000) MAPT mutations in exon 10, from patients or carriers with the G389R MAPT mutation in exon 13 (Murrell et al., 1999) as well as iPSCs from a CBD patient carrying the A152T mutation and from two PSP patients without MAPT mutations, providing additional opportunities for stem cell-based disease modeling. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.